Failure to Achieve Commercial Adoption: Quantum-Si's success depends on the widespread adoption of its protein sequencing platform and consumables by researchers and clinicians. There is no guarantee that the market will embrace their technology over existing or competing methods, or that their platform will demonstrate sufficient advantages to justify its cost and integration into workflows.

Intense Competition and Rapid Technological Change: Quantum-Si operates in a highly competitive and rapidly evolving life sciences tools market. They face competition from established companies offering protein analysis tools, as well as new entrants developing alternative sequencing or analysis technologies, which could render their technology obsolete or less competitive.

Need for Additional Capital and Future Dilution: Quantum-Si has incurred significant losses and will require substantial additional funding to support its research and development activities, expand commercial operations, and achieve profitability. There is no assurance that they will be able to raise sufficient capital on favorable terms, or that future financing will not result in significant dilution for existing shareholders.